Zepzelca® (lurbinectedin) in combination with atezolizumab approved as first-line maintenance therapy for extensive-stage small cell lung cancer in Kuwait
Stockholm, Sweden, September 4, 2026 – Immedica announces that Zepzelca® (lurbinectedin) in combination with atezolizumab (Tecentriq®) has been approved as a maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide in Kuwait. “This approval represents another step forward in our efforts to make innovative treatment options available to patients with extensive-stage small cell lung cancer in the Middle East. We are pleased to support
Read releases like this the second they cross the wire.
1,200+ feeds from 80+ newswires in one live cockpit — saved searches, instant alerts, AI summaries. 7-day free trial, no card required.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live on PPN World.
PPN Source →